Celgene and IMIDomics are teaming up to develop new approaches to treating immune-mediated inflammatory diseases (IMIDs) like lupus. The collaboration will give Celgene access to Barcelona-based IMIDomics’ database, which includes treatment and molecular data from patients who have the diseases. Kay goals are to identify new biomarkers for the disorders…
Servier and ILTOO Pharma have joined forces with an exclusive license agreement for the development and commercialization of the investigational drug ILT-101 (low-dose interleukin-2) to target systemic lupus erythematosus (SLE) and other autoimmune diseases. The companies expect that results of the ongoing Phase 2 clinical trial (NCT02955615)…
Women with systemic lupus erythematosus (SLE) receiving immunosuppressive treatment may be at risk of developing high-grade cervical dysplasia and cervical cancer, compared to patients receiving hydroxychloroquine therapy alone. Although more studies are necessary to confirm these findings, researchers emphasized that SLE women should consider being vaccinated against the human papillomavirus (HPV)…
Patients with systemic lupus erythematosus (SLE) are twice as likely to suffer a potentially fatal pulmonary embolism (PE) as people without this form of lupus, according to researchers at Atlanta’s Morehouse School of Medicine. Their study, “Prevalence of Pulmonary Embolism Among Systemic Lupus Erythematosus Discharges,” appeared in the Journal of Clinical Rheumatology.
A recent 12-year follow-up study performed on first-degree relatives (FDRs) of patients with systemic lupus erythematosus (SLE) showed an increased frequency of autoantibodies such as anti-nuclear antibodies (ANA) when compared to healthy controls. The study, “Autoantibodies persist in relatives to systemic lupus erythematosus patients during 12 years follow-up,” was published…
The presence of antiphospholipid antibodies (aPL) in circulation may aid identify patients at risk for pulmonary hypertension (PH) and associated pulmonary arterial hypertension (PAH) among people who already have systemic lupus erythematosus (SLE). So says a study, “Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension:…
Pfizer, the Lupus Research Alliance and Tata Consultancy have created a smartphone app that allows lupus patients to record and report fatigue and other symptoms in real time. The app’s effectiveness will be evaluated in a clinical trial expected to start at the end of this month. The study (NCT03142711) will be…
Aurinia Pharmaceuticals has started a Phase 3 clinical trial of voclosporin’s ability to treat lupus nephritis, a lupus-generated condition that causes kidneys to become inflamed and eventually fail. The double-blind, placebo-controlled AURORA trial (NCT03021499) will include about 320 patients. It will determine if a combination of voclosporin and a…
Researchers at Denver’s National Jewish Health have prevented autoimmune disease in mice prone to a lupus-like illness by eliminating a protein called T-bet. This protein, which helps transform a type of white blood cell into an age-associated B-cell (ABC), may be a possible therapeutic target for treating lupus, multiple sclerosis, Crohn’s disease…
The National Alliance for Hispanic Health is making a special effort during the current Lupus Awareness Month to increase awareness of the disease among Hispanics, including creating a Spanish-language fact sheet. “Very few Hispanics are aware of lupus, even though Hispanic women are among those with a higher prevalence of the disease,”…